Ariyawardana Anura, Pallegama Ranjith, Sitheeque Mohaideen, Ranasinghe Ajith
Department of Oral Medicine and Periodontology, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
J Investig Clin Dent. 2012 May;3(2):98-102. doi: 10.1111/j.2041-1626.2011.00109.x. Epub 2011 Dec 19.
The aim of this retrospective study was to evaluate the outcome of medical treatment of classic trigeminal neuralgia and to assess the factors affecting the choice of drug regimen (single or multiple), and the duration of treatment for pain control.
A total of 260 consecutive patients were included in the study. Sixty-one patients with less than 6 months' follow up were excluded. All patients were treated with carbamazepine alone or in combination with other drugs. The dosage was adjusted according to the level of pain control and side-effects.
Treatment was terminated in 99 patients (49.7%) after a mean follow-up period of 36.46 months (standard deviation: ±26.5). Of these, 39.4% were on a single drug. Carbamazepine was the drug used in 36 patients. The rest (61%) needed various combinations of drugs. One-hundred patients (50.3%) continued with medical treatment during the follow-up period. Of these, 67.4% were on multi-drug therapy.
The present study showed that the administration of multidrug regimens is a useful alternative in controlling trigeminal neuralgia in patients who are unable to tolerate higher doses of carbamazepine. Age, sex, ethnicity, and the side of affliction did not have a significant influence on the choice of drug regimen and the duration of treatment for pain control.
本回顾性研究旨在评估经典三叉神经痛的药物治疗效果,并评估影响药物治疗方案(单一或多种)选择以及疼痛控制治疗时长的因素。
共有260例连续患者纳入本研究。61例随访时间不足6个月的患者被排除。所有患者均接受卡马西平单药治疗或联合其他药物治疗。剂量根据疼痛控制水平和副作用进行调整。
在平均随访36.46个月(标准差:±26.5)后,99例患者(49.7%)终止治疗。其中,39.4%使用单一药物。36例患者使用卡马西平。其余患者(61%)需要多种药物联合使用。100例患者(50.3%)在随访期间继续接受药物治疗。其中,67.4%接受多药治疗。
本研究表明,对于无法耐受高剂量卡马西平的患者,多药联合治疗方案是控制三叉神经痛的一种有效替代方法。年龄、性别、种族和患病部位对药物治疗方案的选择以及疼痛控制治疗时长没有显著影响。